← ANALYST RATINGS · TIPRANKS
BeOne Medicines (ONC): analyst forecast and price target
Analyst consensus
Strong Buy13 Buy0 Hold0 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $427, the highest $466, the lowest $370. The average is +15.8% from the last price of $369.
Analyst ratings 21
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $430 → $435+1.2% | Buy | +17.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $430 → $435+1.2% | Buy | +17.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $417 → $423+1.4% | Buy | +14.6% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $402 → $408+1.5% | Buy | +10.6% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $433 → $439+1.4% | Buy | +19.0% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $428 → $434+1.4% | Buy | +17.6% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $459 | Buy | +24.4% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $405 → $425+4.9% | Buy | +15.2% | Assigned | 16.10.26on TipRanks 08:25 | −0.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $427 → $430+0.7% | Buy | +16.5% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $427 → $430+0.7% | Buy | +16.5% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $415 → $417+0.5% | Buy | +13.0% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $400 → $402+0.5% | Buy | +8.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $430 → $433+0.7% | Buy | +17.3% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $425 → $428+0.7% | Buy | +16.0% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $418 → $420+0.5% | Buy | +13.8% | Reiterated | 08.10.26on TipRanks 22:25 | +0.6%next day −1.1% · 5 days +6.1% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $450 → $459+2.0% | Buy | +24.4% | Reiterated | 08.10.26on TipRanks 09:05 | −3.4%next day +0.6% · 5 days +7.1% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $431 → $427−0.9% | Buy | +15.7% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $431 → $427−0.9% | Buy | +15.7% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $419 → $415−1.0% | Buy | +12.4% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $404 → $400−1.0% | Buy | +8.4% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $435 → $430−1.1% | Buy | +16.5% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $429 → $425−0.9% | Buy | +15.2% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 05.10.26on TipRanks 08:45 | +0.3%next day −0.2% · 5 days −3.5% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $425 → $445+4.7% | Buy | +20.6% | Reiterated | 01.10.26on TipRanks 07:35 | −2.1%next day −0.9% · 5 days −3.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $426 → $431+1.2% | Buy | +16.8% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $426 → $431+1.2% | Buy | +16.8% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $414 → $419+1.2% | Buy | +13.5% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $399 → $404+1.3% | Buy | +9.5% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $429 → $435+1.4% | Buy | +17.9% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $424 → $429+1.2% | Buy | +16.2% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $407 → $415+2.0% | Buy | +12.4% | Reiterated | 10.09.26on TipRanks 05:31 | −2.0%next day +0.5% · 5 days +2.8% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $450 | Buy | +21.9% | Reiterated | 25.08.26on TipRanks 06:35 | +0.9%next day −0.2% · 5 days −4.2% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $340 → $370+8.8% | Buy | +0.3% | Assigned | 09.08.26on TipRanks Aug 10 08:20 | +3.1%next day +0.4% · 5 days +1.0% | ↗ |
| Jill Wu★★★★★★★★★★#513 · hits 52% · avg +26.4% | CMB International Securities | $392 → $442+12.7% | Buy | +19.8% | Reiterated | 07.08.26on TipRanks 12:30 | +5.0%next day +3.1% · 5 days −0.6% | ↗ |
| David Li★★★★★★★★★★#7287 · hits 48% · avg +1.0% | Bank of America Securities | $404 → $423+4.8% | Buy | +14.6% | Reiterated | 06.08.26on TipRanks 07:50 | +0.9%next day +5.0% · 5 days +6.7% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $400 | Buy | +8.4% | Reiterated | 06.08.26on TipRanks 07:15 | +0.9%next day +5.0% · 5 days +6.7% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $453 → $466+2.9% | Buy | +26.3% | Assigned | 06.08.26on TipRanks 05:55 | +0.9%next day +5.0% · 5 days +6.7% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $396 → $405+2.3% | Buy | +9.7% | Reiterated | 06.08.26on TipRanks 05:55 | +0.9%next day +5.0% · 5 days +6.7% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $395 → $405+2.5% | Buy | +9.7% | Reiterated | 06.08.26on TipRanks Aug 5 09:25 | +1.6%next day +0.9% · 5 days +9.3% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $416 → $418+0.5% | Buy | +13.3% | Reiterated | 06.08.26on TipRanks Aug 5 08:35 | +1.6%next day +0.9% · 5 days +9.3% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $420 → $430+2.4% | Buy | +16.5% | Reiterated | 05.08.26on TipRanks Aug 6 06:55 | +1.6%next day +0.9% · 5 days +9.3% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $424 → $454+7.1% | Buy | +23.0% | Reiterated | 05.08.26on TipRanks 17:50 | +0.9%next day +5.0% · 5 days +6.7% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $333 → $380+14.1% | Buy | +3.0% | Upgrade | 12.07.26on TipRanks 20:25 | +2.5%next day +0.5% · 5 days +3.1% | ↗ |
| Unknown Analyst | Leerink Partners | $364 → $367+0.8% | Buy | −0.6% | Reiterated | 15.05.26on TipRanks 22:05 | 0.0%next day +2.0% · 5 days +1.6% | ↗ |
| Rebecca Liang★★★★★★★★★★#1494 · hits 69% · avg +26.0% | Bernstein | $412 | Buy | +11.6% | Reiterated | 18.03.26on TipRanks 07:50 | −0.4%next day +0.4% · 5 days +0.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering BeOne Medicines
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $422 at a price of $366 (+15.2%); now: $427 at $369 (+15.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 6 | 6 | 6 | 0 | 0 |
| Buy | 24 | 22 | 25 | 25 | 22 | 20 |
| Hold | 2 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.89 (from $1.56 to $2.24). Last quarter: $2.05.
Sales
Next quarter’s sales estimate — $1.8B (from $1.7B to $1.8B). Last quarter: $1.7B.
Best top-analyst consensus in the sector · Healthcare
About BeOne Medicines
- CEO: John V. Oyler
- Employees: 12,000
- Aeschengraben 27, Basel, PA, 4051, CH
- beonemedicines.com
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Data from the stock’s TipRanks forecast page, read 38 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗